Company Profile
Certara Stock Price, News & Analysis
Company overview
Business overview
Certara is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Certara is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Certara follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Certara sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
CERT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Certara's catalysts are Simcyp adoption, model-informed drug-development bookings, and life-science software demand. The business improves when pharma customers keep using the platform as part of their everyday development workflow.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Certara Automates Scientific Workflows with Phoenix® Cloud
Source: Certara
- 02
Certara Reports Third Quarter 2025 Financial Results
Source: Certara
- 03
Certara Appoints Jon Resnick as Chief Executive Officer
Source: Certara
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.